Press Release
« Back
TG Therapeutics, Inc. Announces Clinical Data Presentations at Upcoming Conferences
May 06, 2014
- Single Agent Study Updates on TG-1101 and TGR-1202 to be Presented at ASCO 2014
- Combination Study Data of TG-1101 plus Ibrutinib to be Presented at EHA 2014
-
Combination Study Data of TG-1101 and TGR-1202 to be Presented at the 2014
Pan Pacific Lymphoma Conference
First, at the 50th Annual Meeting of the
The presentation schedule at ASCO 2014 is as follows:
Poster Presentation & Discussion:
-
Title: Activity of TGR-1202, a novel once-daily PI3K delta inhibitor, in patients with relapsed or refractory hematologic malignancies.
- Abstract Number: 2513
-
Presentation Date & Time: Friday, May 30, 2014,
1:00 PM - 4:00 PM CT - Poster Display: Room E354b, Poster Board #27
-
Presenter: Howard A. Burris, MD,
Sarah Cannon Research Institute ,Nashville, TN
Discussion Session
-
4:30 -
5:45 PM CT ; E Arie Crown Theater
Poster Presentation:
-
Title: A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.
- Abstract Number: 8524
-
Presentation Date & Time: Friday, May 30, 2014,
1:00 PM - 4:00 PM CT - Poster Display: Room S405, Poster Board #4
-
Presenter: Owen A. O'Connor, MD, PhD,
Columbia University Medical Center ,New York, NY
In addition, data from the first combination study of TG-1101 and ibrutinib as well as data from the single agent studies for both TG-1101 and TGR-1202 will be presented at the 19th
Finally, a clinical update on the combination study of TG-1101 and TGR-1202 will be presented at the 2014
A copy of the ASCO abstracts will be available online on
ABOUT
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101 and TGR-1202 will not be reproduced in additional patients or in future studies; the risk that TGR-1202 will not
produce satisfactory safety and efficacy results to warrant further development following the completion of the current phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the
TGTX - G
CONTACT:Source:Jenna Bosco Director - Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4351 Email: ir@tgtxinc.com
News Provided by Acquire Media